Adaptive clinical trials

Lead Research Organisation: MRC Biostatistics Unit

Abstract

Explain, in simple lay language, the outcomes and significance of the research. You should include what the research is trying to achieve and why this is important, and brief notes on the context of the research and the methods (see Guidance Notes).
Classically designing a clinical trial involves making assumptions about various attributes, such as the treatment effect, before any data are collected. The aim of our programme is to introduce novel designs that are more flexible. The rigidity of the classic design can lead to failed studies due to wrong assumptions such as using an optimistic treatment effect to limit the size of the study. Our novel designs will allow the use of accrued information in many ways; this includes stopping the study early for futility or efficacy, re-assessing the size of the study and recruiting more patients if need be altering dose choices during the study and identifying subgroups of patients who respond the best to treatment. Our overall goal is to minimise the number of people needed within a study whilst maintaining the statistical rigour needed to correctly answer the scientific questions.

Technical Summary

Given the increase in costs and high risk of developing new interventions smarter clinical designs are needed to make the best use of limited resources. The aim is that the leaner development plans will require fewer patients and shorter timelines. Our programme builds on that of the past where we have contributed to the design of numerous trials and continue to build collaborations in the area of adaptive designs. Most of the Hub Network for Trials Methodology Research stakeholders identified the need for more methodological research in the area of adaptive designs. This program can expand its research, training and software provision to meet this need and enable the translation of theory into future clinical trial practice. We aim to develop new trial designs to handle multiple treatments and multiple interim analyses that minimise the expected number of patients. There is an increasing need to consider diseases as multiple phenotypes and to find treatments that are effective for particular subgroups. Our methods aim to minimise the time of the clinical development and the amount of exposure time for patients whilst obtaining robust evidence for treatment safety and/or efficacy.

Each adaptive design is tailor-made for each clinical situation and the methodological problems are diverse. A clear example of this is the increasing need to design phase I trials for drug combination products. Currently phase I trial designs are very conservative using inefficient rule-based designs. We aim to not only develop better methods but to apply them in real trials, promote them in the clinical community and support clinical trials statisticians. We propose to develop more generalised methodology, such as methods that are robust to model assumptions, that can be applied across a broad range of trials to improve accessibility.

Of particular interest are study designs that can stop early and thus achieving a smaller expected sample size. Sample size re-estimation is another key area, where uncertain sample size parameters can be estimated part-way through a trial; we want to find optimal ways of how to do sample size re-estimation and how to use intermediate outcomes in these calculations.

Future clinical development will involve using more information from intermediate markers of efficacy and/or predictive/prognostic markers to help reduce the time and resources needed to get treatments to bedside. Many of our future proposals are looking to extend current methodology to optimally incorporate these new developments.

Publications

10 25 50

publication icon
Bowden J (2017) Unbiased estimation for response adaptive clinical trials. in Statistical methods in medical research

publication icon
Bowden J (2016) Weighing Evidence "Steampunk" Style via the Meta-Analyser. in The American statistician

 
Description New adaptive design mentioned as 'research highlight' in Nature Reviews Clinical Oncology
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
URL http://www.nature.com/nrclinonc/journal/vaop/ncurrent/full/nrclinonc.2015.138.html
 
Description Using Historical Data training course
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Adrian Mander was invited to create a course for GSK on the use of historical data to improve the design of clinical trials. This is a hugely important issue and has the ability to make efficiency gains for early phase clinical trials. GSK are already using the techniques in practice and this course was to enable a better understanding and wider usage of these techniques
 
Description AIM-HY
Amount £43,679 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2015 
End 12/2019
 
Description EPAD-
Amount € 654,000 (EUR)
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Multiple
Country European Union (EU)
Start 04/2015 
End 03/2020
 
Description HTMR Network Award
Amount £3,071 (GBP)
Funding ID N97 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2018 
End 09/2018
 
Description INNODIA
Amount € 500,000 (EUR)
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Multiple
Country European Union (EU)
Start 10/2015 
End 09/2022
 
Description MBU grant
Amount £17,059 (GBP)
Organisation University of Edinburgh 
Department MRC DPFS Resoure Centre
Sector Multiple
Country United Kingdom
Start 11/2014 
End 02/2017
 
Description NIHR HTA (Epilepsy Nurse)
Amount £52,826 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2013 
End 11/2015
 
Description NIHR XP grant
Amount £10,597 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 09/2015 
End 03/2020
 
Description NIHR- Jonathan Mant
Amount £85,434 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2015 
End 03/2020
 
Description AZ - Jodrell phase I 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution We have only just initiated this collaboration so we have been shortlisting and trying to recruit
Collaborator Contribution Shortlisting and recruiting
Impact None so far
Start Year 2014
 
Description AZ - Jodrell phase I 
Organisation Cancer Research UK Cambridge Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution We have only just initiated this collaboration so we have been shortlisting and trying to recruit
Collaborator Contribution Shortlisting and recruiting
Impact None so far
Start Year 2014
 
Description AZ joint postdoc 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution We have a joint position to look at Phase I dose escalation designs
Collaborator Contribution Provide advice and scientific directin.
Impact None yet.
Start Year 2017
 
Description CRUK grant 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution I have provided expertise in efficient statistical analysis of phase II oncology trials using the RECIST criteria.
Collaborator Contribution Individuals at the University of Birmingham provided clinical and applied statistical expertise that has helped us jointly develop a programme of work for a grant application.
Impact With individuals at the University of Birmingham, I have successfully applied for a Cancer Research UK grant, to start in Jan 2015.
Start Year 2013
 
Description CTU joint positin 
Organisation Cambridge University Hospitals NHS Foundation Trust
Department Cambridge Clinical Trials Unit
Country United Kingdom 
Sector Hospitals 
PI Contribution We have a joint position to work on dual agent dose escalation studies.
Collaborator Contribution Scientific input
Impact None yet
Start Year 2017
 
Description Cambridge CTU 
Organisation Addenbrooke's Hospital
Department Cambridge Cancer Trials Centre
Country United Kingdom 
Sector Hospitals 
PI Contribution We collaborate on several trials and have a joint position. We also provide computing to Simon Bond
Collaborator Contribution They collaborate with us on clinical trial designs
Impact None so far
Start Year 2013
 
Description Diabetes Research 
Organisation University of Cambridge
Department Cambridge Institute for Medical Research (CIMR)
Country United Kingdom 
Sector Academic/University 
PI Contribution Involved in multiple trials involving Il-2 dose/frequency finding
Collaborator Contribution They ran the trial and gave the scientific steer
Impact Drafted publications and presentations
Start Year 2011
 
Description MAMS grant 
Organisation Lancaster University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provided input to multiple submitted papers, including two in 2013/2014, that covered multi-arm multi-stage trials and phase II oncology trials. I provided input into writing a grant that was funded by the MRC methodology research panel. I was a co-investigator on this grant.
Collaborator Contribution Dr Thomas Jaki has provided complementary expertise into the writing of papers and the grant application.
Impact Multiple papers published since 2012 (recorded under publications). Successful grant application.
Start Year 2011
 
Description Maxine's PhD 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution I am the academic supervisor of this CASE award, the industry partners are within GSK. I give the main methodology direction of the project
Collaborator Contribution Partners give scientific and practical guidance into the project
Impact None so far
Start Year 2013
 
Description Philips Research Cambridge collaboration 
Organisation Philips Research Cambridge
Country United Kingdom 
Sector Private 
PI Contribution I am the academic supervisor for a Ph.D. student on the subject of 'Adaptive designs for telehealth trials'
Collaborator Contribution Individuals at Philips Research Cambridge have provided expertise on telehealth trials and have hosted the student for a research visit. They also provided a financial contribution to the EPSRC case award that funds the studentship.
Impact The student (Lisa Law) started in October 2013 and has been upgraded to full Ph.D. student status in October 2014. During her time as a student, Lisa published two papers. Unfortunately Lisa chose to drop out of the PhD programme in 2016 and submitted what she had done up to that point for a MPhil degree, which she received successfully.
Start Year 2012
 
Description Polypill 
Organisation University of Cambridge
Department Cambridge Institute of Public Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Co-applicant on program grant, developing trial design with research team.
Collaborator Contribution Scientific direction and running trial
Impact All outputs are still being developed
Start Year 2011
 
Description Roche phase I trial design 
Organisation Roche Pharmaceuticals
Country Global 
Sector Private 
PI Contribution We have engaged with industry to try and implement methods in practice. We have had some meetings and some presentations but also we have some joint work ongoing to help implement the PIPE design methodology
Collaborator Contribution The partners have listened and are committed to trying methods out in practice. Currently one of the their phase I trial designs is using the dual-agent design PIPE in one of their early phase trials (ClinicalTrials.gov Identifier: NCT02760797).
Impact None yet, it is still early
Start Year 2014
 
Description SMARTer trial collaboration 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution I have provided expertise on statistical design of adaptive clinical trials to develop a suitable clinical trial design for the needs of the collaborators.
Collaborator Contribution Input on the design and clinical expertise. They have also written a grant application to fund the trials.
Impact We have submitted a paper on the trial design and a grant application to the HTA efficient trial design call (currently at outline stage).
Start Year 2012
 
Description WRAP study 
Organisation Medical Research Council (MRC)
Department MRC Human Nutrition Research Unit
Country United Kingdom 
Sector Public 
PI Contribution Trial design expertise and how to handle missing data
Collaborator Contribution Scientific direction and running the trial
Impact No direct outputs yet
Start Year 2012
 
Title CRM 
Description A stata module to design a continual reassessment trial 
Type Of Technology Software 
Year Produced 2013 
Open Source License? Yes  
Impact There have been some downloads of this module but no references to it as of yet. 
 
Title GROUPSEQ: Stata module providing functions to determine group sequential trial designs 
Description A selection of functions to determine the boundaries and sample size required by several common group sequential designs, for two-arm trials with continuous outcome variables. 
Type Of Technology Software 
Year Produced 2017 
Impact Several trial statisticians and methodologists have subsequently been in contact to ask for further information around the design of group sequential clinical trials, particularly in Stata. 
URL https://ideas.repec.org/c/boc/bocode/s458345.html
 
Title MVTNORM: Stata module to work with the multivariate normal and multivariate t distributions 
Description A set of commands that allow users to compute the distribution function, density, equi-coordinate quantiles, and random vectors of the multivariate normal and multivariate t distributions. Any non-degenerate cases of the multivariate normal and multivariate t distributions can be worked with, along with a particular class of non-central multivariate t distributions. The commands are written in a combination of Stata and Mata for speed. 
Type Of Technology Software 
Year Produced 2017 
Impact MVTNORM has subsequently allowed the creation of the GROUPSEQ module for designing group sequential clinical trials. 
URL https://ideas.repec.org/c/boc/bocode/s458043.html
 
Title MVTNorm 
Description The Stata module calculates multivariate statistics. 
Type Of Technology Software 
Year Produced 2015 
Open Source License? Yes  
Impact The stata module can be used in an group sequential /MAMS clinical trial and the companion stata journal article is in preparation. 
 
Title Simon2stage 
Description Stata module to design a simon two-stage design 
Type Of Technology Software 
Year Produced 2012 
Open Source License? Yes  
Impact None so far but this was linked to a publication and those methods have been cited so this software is being used. 
 
Title Simpute 
Description A stata module to due simple imputaton 
Type Of Technology Software 
Year Produced 2013 
Open Source License? Yes  
Impact It has been downloaded but no citations as of yet. 
 
Description Adaptive Designs Talk at PSI conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This talk raised the awareness of the Hub Network activities in adaptive trial designs. There was some discussion of the methods and discussion about being available for consultative purposes.

No notable impacts
Year(s) Of Engagement Activity 2013
 
Description Adaptive Designs symposium at the Institute of Psychiatry 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact There was some interesting debates about adaptive designs

Raised our visibility in Psychiatry
Year(s) Of Engagement Activity 2013
 
Description Adaptive designs training course at Pavia University, Italy 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact We gave a 3 day training course on adaptive trial designs with practicals in R.
Year(s) Of Engagement Activity 2017
 
Description Armitage Lectures 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Annual workshop and lecture created and hosted by the MRC Biostatistics Unit, to honour the immense contributions of Professor Peter Armitage who was at the unit from 1947 to 1961, and whose work is recognised throughout the world as achieving a successful balance between methodological rigour and applied commonsense, to which all statisticians aspire. An eminent medical statistician visits for a week and works with members of the unit. The highlight is the Armitage Lecture, where more than 100 delegates attend. This event raises the unit research profile and creates new collaborations.
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016
URL https://www.mrc-bsu.cam.ac.uk/news-and-events/armitage-lectureships-and-workshops/
 
Description BSU Open Day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Unit held open day as part of MRC Festival of Medical Research.

The aim of the open day was to welcome secondary school students and members of the general public to come to the unit, find out about the research the unit does, and to take part in activities that illustrate BSU research, with the overall theme being 'Fun with statistics'. An open day of this format was a first for the unit and overall it was a very successful event. There were 40 attendees over a 4 hour event. All attendees pre-booked and were split into 4 groups for a 1 hour session comprising of an introduction, participation in hands-on activities, and a brief careers talk. The small groups and length of session allowed for quality engagement between the scientists and the audience.

Feedback from the attendees was very positive, and the wider MRC Festival activities that took place in Cambridge demonstrated the benefits in delivering these types of events.
Year(s) Of Engagement Activity 2016
URL http://www.mrc-bsu.cam.ac.uk/bsu-open-day-2016-why-are-statistics-important/
 
Description Cambridge Science Festival 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Each year BSU participate in Cambridge Science Festival - members of the general public explore and discuss issues of scientific interest and concern, through a series of different events. The festival also aims to raise aspirations by encouraging young people to consider a career in science, technology, engineering or mathematics.

BSU take part over two full days - 'Science Saturday' and the 'Cambridge Biomedical Campus' day. The unit presents a stand with 4 - 5 interactive activities that each communicate a basic statistical method or idea, representing one of the four research themes in the unit. Each year a new activity is developed and delivered requiring scientific input from staff and students across the unit. Over the two days, BSU engage with approximately 500 adults and children who visit the festival.
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016
URL http://www.sciencefestival.cam.ac.uk/
 
Description Contributed talks at the 18th INFORMS Applied Probability Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact SV gave contributed talks at the 18th INFORMS Applied Probability Conference and the 7th Greek Stochastics meeting. Talk entitled "Novel bandit-based solutions for practical stochastic scheduling problems".
Year(s) Of Engagement Activity 2015
URL http://www.stochastics.gr/meetings/eta/
 
Description Dose finding talk (Charleston) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Talk sparked a discussion on various dose-ranging aspects

No immediate impacts
Year(s) Of Engagement Activity 2014
 
Description Dose ranging talk (Cambridge) invited by the Cambridge Discussion Group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Talk sparked a debate about these methods.

Made some industry links within Roche and Astra Zeneca
Year(s) Of Engagement Activity 2014
 
Description Invited presentation at an early phase clinical conference (Paris) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I presented a novel clinical trial design on dual-agent dose escalation, there was a lot of interest from academics and industry. Since then I have worked closely with a member of Roche pharmaceuticals on how to implement these methods in practice.
Year(s) Of Engagement Activity 2015
 
Description Invited talk at CLDAG 2017 conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I was an invited speaker to this international statistical conference. I spoke about adaptive dose ranging trial designs.
Year(s) Of Engagement Activity 2017
 
Description Invited talk at the PSI meeting on Extrapolation 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact I was invited to give a talk on using historical data in trial inference and design.
Year(s) Of Engagement Activity 2017
 
Description Invited talk for the Breathlessness conference (Cambridge) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Adrian Mander gave a presentation on the various ways to adapt clinical trials to the area of palliative and end of life care. There has been numerous discussions since the talk by email with plans to produce a paper introducing this area to the wider audience undertaking these challenging trials.
Year(s) Of Engagement Activity 2015
 
Description Invited talk on early phase clinical trial designs (London) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact 80 members of clinical trials units attended a workshop run by the NCRI, the talk on early phase designs was aimed at changing practice and how we design phase I trials.
Year(s) Of Engagement Activity 2015
 
Description Invited to give a departmental seminar on adaptive designs (Norwich) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Policymakers/politicians
Results and Impact Around 30 members of the clinical trials unit attended my talk on adaptive clinical trials, there was a great deal of interest and promises of future collaboration as there was a recognition that these methods will be needed in the near future
Year(s) Of Engagement Activity 2015
 
Description NCRI talk on phase I trials (Liverpool) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact There was some debate and discussion.

None so far but this was the start of raising the awareness of better trials in oncology
Year(s) Of Engagement Activity 2012
 
Description Oral presentation at the 23rd London Stata Users Group Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presented a talk entitled "Group sequential clinical trial designs for normally distributed outcome variables".
Year(s) Of Engagement Activity 2017
URL http://www.timberlake.co.uk/2017-stata-user-group-abstracts
 
Description Oral presentation at the Adaptive Designs and Multiple Testing Procedures Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presented a talk entitled "A two-stage Fisher exact-test for multi-arm trials with binary endpoints".
Year(s) Of Engagement Activity 2017
URL https://www.mrc-bsu.cam.ac.uk/event/adaptive-designs-multiple-testing-procedures-workshop-2017/
 
Description Oral presentation at the CEN-ISBS 2017 Joint Conference on Biometrics and Biopharmaceutical Statistics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented a talk, in a contributed session, entitled "Do single-arm trials have a role in drug development plans incorporating randomised trials?".
Year(s) Of Engagement Activity 2017
URL http://cenisbs2017.org/
 
Description Phase I course in dose-escalation adaptive designs at UCL 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact This was a two day training course aimed at statisticians in early phase designs. There were also regulators at this meeting.
Year(s) Of Engagement Activity 2017
 
Description Poster presentation at the 38th Annual Conference of the International Society of Clinical Biostatistics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented a poster entitled "Admissible multi-arm stepped-wedge cluster randomized trial designs".
Year(s) Of Engagement Activity 2017
URL http://iscb2017.info/
 
Description Poster presentation at the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented a poster entitled "Blinded and unblinded sample size re-estimation procedures for stepped wedge cluster randomised trials".
Year(s) Of Engagement Activity 2017
 
Description Poster presentation at the Current Developments in Cluster Randomised Trials and Stepped Wedge Design workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presented a poster entitled "Design of an adaptive cluster randomised crossover trial, with application to the STRIVE trial".
Year(s) Of Engagement Activity 2017
 
Description Research Design Service (LONDON) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact I was invited to talk about adaptive clinical trials as part of a workshop of talks. There is a call for novel designs and my talk covered various methods that can be used to make trials more efficient
Year(s) Of Engagement Activity 2015
 
Description Talk about adaptive enrichment designs (Institute of Cancer Research 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact We had a day long discussion about various potential collaborations

There were no massive impacts, a similar study was planned in their institute but it was too late to help improve it.
Year(s) Of Engagement Activity 2014
 
Description Talk at Clinical Trials in Small Populations workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact SV was co-organiser of worksop, gave a tutorial on `Response-adaptive randomisation' during Day 1 and also contributed to one of the talks during Day 2 entitled 'Bringing patient population size into clinical trial design using response-adaptive randomisation'.
Year(s) Of Engagement Activity 2015
 
Description Talk at Lancaster University - Methodological work to make bandit models suitable to design (and improve) multi-armed clinical trial 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact SV invited speaker at workshop that gathered worldwide experts on ''bandit problems" (reinforcement learning bandits, restless bandits, non-parametric bandits, Bayesian bandits, etc., ) to discuss recent methodological advances and applications. SV spoke about recent methodological work to make bandit models suitable to design (and improve) multi-armed clinical trials.
Year(s) Of Engagement Activity 2016
 
Description Talk at the local RSS NW group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact A review talk on the multiple bandit-based designs publications of Sofia Villar
Year(s) Of Engagement Activity 2016
 
Description Talk on adaptive designs to Astra Zeneca 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact There was much interest in the methods and raised awareness of our group to the company

Since this talk we have secured a data sharing agreement and collaboration.
There are also 3 AZ post-docs that we have been linked with
Year(s) Of Engagement Activity 2013
 
Description Workshop on Recent and Future Trends in Biostatistics 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact One-off, unique workshop for early career statisticians on the theme of recent and future trends in biostatistics. Workshop included three plenary speakers and six contributed presentations, as well as interactive presentations and a panel discussion. Many attendees reported that they found the workshop very useful. Delegate feedback included:"A great mix of sessions", "A very enjoyable workshop", "Workshop opened itself to initiate conversations with other like minded individuals", "I have come away with a lot of information on new and exciting statistical techniques". One delegate has used information from panel discussion debate on the topic of biostatistics training, to quote in their career development review.
Year(s) Of Engagement Activity 2017
 
Description Workshop provision at the Society for Social Medicine 61st Annual Scientific Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Assisted in the organisation and delivery of a workshop entitled "Novel trial designs and analytical methods for evaluating complex public health interventions: a discussion", in collaboration with members of the MRC Lifecourse Epidemiology Unit.
Year(s) Of Engagement Activity 2017